Melatonin is widely known as a sleep aid, but clinical research increasingly explores its broader physiological roles. Pioneering integrative physicians like Dr Matthias Kraft have highlighted melatonin's antioxidant capacity, mitochondrial support, immune modulation and potential roles across multiple medical specialties.
In sleep medicine, low-dose melatonin (0.5–3 mg) is well established for delayed sleep phase disorder, jet lag and shift work adaptation. Higher doses (10–20 mg) are being investigated for non-sleep applications including neuroprotection, cardiovascular support and adjunctive oncology care.
Mechanistically, melatonin is one of the most powerful endogenous antioxidants known, with the unique ability to cross both the blood-brain barrier and mitochondrial membranes. This makes it particularly relevant for conditions involving oxidative stress in the central nervous system or mitochondrial dysfunction.
In integrative oncology contexts, high-dose melatonin has been studied as adjunctive therapy alongside chemotherapy, with signals of improved tolerability and possible synergy with certain agents. This remains investigational and must be coordinated with the treating oncologist due to potential interactions.
For most adults seeking sleep support, the smallest effective dose taken consistently 30 minutes before bed in a dim environment produces the best results. Higher-dose protocols for non-sleep applications should only be undertaken under qualified medical supervision.
